News
Biognosys schließt Wiederverkaufsvertrag für Proteomik-Software „Spectronaut“ mit führendem Anbieter von Massenspektrometriesystemen ab
- Spectronaut® von Biognosys, die führende herstellerunabhängige Software für die DIA-Proteomik, ist jetzt direkt von Thermo Fisher Scientific im Rahmen einer Wiederverkaufsvereinbarung erhältlich
CARBIOS und FCC Environment planen gemeinsam die Errichtung einer PET-Biorecycling-Anlage auf Basis der lizenzierten Technologie von CARBIOS in Großbritannien
Clermont-Ferrand (Frankreich) und Doncaster (England), Dienstag, 06. August (06:45 Uhr MESZ). CARBIOS, (Euronext Growth Paris: ALCRB), ein Pionier in der Entwicklung und Industrialisierung
Biognosys und Alamar Biosciences schließen strategische Partnerschaft im Bereich Proteomik zur Förderung der Biopharma- und Präzisionsmedizin-Forschung
- Strategische Partnerschaft erweitert die Dienstleistungen von Biognosys um die NULISA-Assays von Alamar sowie die gemeinsame wissenschaftliche Forschung im Bereich der biofluidbasierten Proteomik
Biognosys erweitert US-Präsenz mit neuer CRO-Einrichtung für Proteomik in Massachusetts
- Die neue CRO-Einrichtung für Proteomik-Dienstleistungen in Newton, Massachusetts, gewährleistet eine größere Nähe zu den US-Kunden
- Das Kompetenzzentrum für Proteomik-Innovationen am Hauptsitz von
shareribs.com - Auftragseingang bei Windkraftanlagen steigt auf Rekordhoch
Colonial Increases Its Stake in SFL
The Colonial Group has approved a simplification of the shareholding structure of its subsidiary SFL which reinforces its Real Estate exposure in Paris and consists in:
-
a contribution by
Siemens Gamesa: Aktie, flieg mit dem Wind
Siemens Gamesa Renewable Energy (WKN: A0B5Z8), kurz SGRE oder Siemens Gamesa, ist ein börsennotierter, international tätiger Hersteller von Windkraftanlagen mit Hauptsitz in Zamudio bei Bilbao
Nordex: Sieht das etwa wie ein Aufstieg aus? Zocker-Trading-Chance!
Acerinox: zuversichtlich ins Jahr 2017!
Banco Popular tauscht Vorstandschef aus
Where Will Sirius XM Stock Be in 5 Years?
With shares down around 60% over the last five years, Sirius XM (NASDAQ: SIRI) has battered its long-term investors. And it's no surprise management turned to a 1-for-10 reverse stock split to keep
Why Intuitive Machines Popped, but Rocket Lab and AST SpaceMobile Stocks Dropped Today
Volatility ran amok among space stocks Tuesday. Shares of lunar explorer Intuitive Machines (NASDAQ: LUNR) rocketed 35.6% through 3 p.m. ET, but rocket maker Rocket Lab (NASDAQ: RKLB) and satcom
Why AST SpaceMobile Stock Popped, Then Dropped
Yesterday's stock market sell-off hurt a lot of stocks, but AST SpaceMobile (NASDAQ: ASTS) wasn't one of them. Defying the market rout, shares of the start-up space company promising satellite
Indra Signs a Framework Agreement to Equip Airports in the United States With Technology for the Surveillance and Monitoring of Surface Aircraft
Indra will supply Surface Awareness Initiative (SAI) systems for the United States Federal Aviation Administration (FAA), the civil aviation authority that manages the country’s air traffic. The
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first
Why Comcast Stock Dropped Today
Shares of cable TV and internet provider Comcast (NASDAQ: CMCSA) stock slipped 2.3%, falling exactly $1 in share price through 12:30 p.m. ET Thursday.
The stock appears to be reacting to breaking
Why AST SpaceMobile Stock Keeps Rocketing Higher
The stock of AST SpaceMobile (NASDAQ: ASTS) popped again on Wednesday, after the satellite communications company announced on Tuesday that it has updated its filings with the International
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.
This press release features multimedia. View the full release
Why Is SpaceX Partnering With John Deere?
Going from a concept in 2015 to beta service in 2021, SpaceX's plan to build a network of fast internet communications satellites has grown from 0 to 10,000 to 2.2
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics,
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in